CBD In The News

Neurotech Releases ASD Medical Cannabis Study Results – Hemp Gazette

July 12, 2022 by Trishah

CBDA is a precursor to CBD. NTI164 contains less than 0.3% THC, which is is the cannabinoid associated with intoxicating effects.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program.

WEBSITE DISCLAIMER

The statements posted on this website by various users are the opinions of the users alone. The administrator of this website, his or her employer(s), affiliates, or employees are not responsible for the content of the statements, and shall not be held liable in any way for the content of these statements. Always consult your attorney before taking any action that may have any legal consequences. The statements and products referred to throughout this site have not been evaluated by the FDA. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult a physician or your health care provider. Always consult a medical doctor before modifying your diet, using any new product, drug, supplement, or doing new exercises. We recommend you educate yourselves on the scientific / nutritional facts.

The information on this website is not legal advice. Consult a lawyer and the laws in your state before buying or selling CBD products.

Please view our full Terms Of Use Agreement for more information and the terms and conditions governing your use of this site.

AMAZON AFFILIATES DISCLAIMER

Constructive Growth LLC are participants in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to amazon.com. Amazon, the Amazon logo, AmazonSupply, and the AmazonSupply logo are trademarks of Amazon.com, Inc. or its affiliates.

web design by trishah